SLC6A3 and schizophrenia: Furthermore, studies have demonstrated reduced DAT uptake in patients with Parkinson’s disease and schizophrenia, with the degree of DAT reduction correlating positively with disease severity (Sampedro et al., 2021; Yang et al., 2024).